CGTX News and Press, Cognition Therapeutics Inc. From 10/11/22

PURCHASE, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), announced the appointment of Paul J. Tiseo, Ph.D. to the newly created role of vice president of clinical development. Dr. Tiseo brings to Cognition more than two decades of strategic and operatio...

PURCHASE, N.Y., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting...

Cognition Therapeutics ( NASDAQ: CGTX ) said it received a $2.14M grant from the National Institute on Aging (NIA) to help complete an ongoing study of CT1812 in adults with mild-to-moderate Alzheimer's disease. The study called SEQUEL will evaluate if CT1812 results i...

PURCHASE, N.Y., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced today that the company has received a $2.14M grant award from the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH), to support completion of t...

PURCHASE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targe...

Cognition Therapeutics press release ( NASDAQ: CGTX ): Q2 GAAP EPS of -$0.25 beats by $0.07 . Cash and cash equivalents on Q2 was approximately $45.8 million. For further details see: Cognition Therapeutics GAAP EPS of -$0.25 beats by $0.07

Ongoing Patient Dosing in SHIMMER Study for DLB and SHINE Study for Alzheimer’s Disease Positive Preliminary Data for Dry AMD Program Presented at ARVO 2022 Proteomics Data from SPARC read out at AAIC PURCHASE, N.Y., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cognition...

The National Institute of Health (NIH) awarded Cognition Therapeutics ( NASDAQ: CGTX ), a clinical-stage pharma focused on age-related degenerative diseases, more than $10M grant on Monday to further support a Phase 2 trial for the company's lead asset CT1812 in dementia. ...

Gainers: CinCor Pharma CINC +66% . Karuna Therapeutics KRTX +61% . 23andMe ( ME ) +22% . Cerevel Therapeutics ( CERE ) +20% . Quoin Pharmaceuticals ( QNRX ) +16% . Losers: Reata Pharmaceuticals RETA -31% . uniQure QUR...

NuZee ( NUZE ) -24% on pricing $3.4M stock offering . Reata Pharmaceuticals ( RETA ) -20% on Q2 earnings release . Palantir Technologies ( PLTR ) -14% on Q2 earnings release . Digital World Acquisition ( DWACW ) -10% . Cognit...